The invention provides [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-yl-methyl]-dimethyl-ammonium napadisylate, pharmaceutical compositions containing it, and its use in therapy.
1. A salt being [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-ylmethyl]-dimethyl-ammonium napadisylate.
2. A salt according to claim 1 which is [2-(4-chloro-benzyloxy)-ethyl]-[2-((R)-cyclohexyl-hydroxy-phenyl-methyl)-oxazol-5-ylmethyl]-dimethyl-ammonium hemi-naphthalene-1,5-disulfonate.
3. A salt according to claim 2 , which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ): 5.3, 10.5, 15.8, and 16.5.
4. A salt according to claim 3 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 1 .
5. A salt according to claim 1 , wherein the salt is an anhydrate.
6. A pharmaceutical composition, wherein the composition comprises:
a salt according to claim 1 , and
a pharmaceutically acceptable adjuvant, diluent, or carrier.
7. A method of treating chronic obstructive pulmonary disease, wherein the method comprises administering a salt according to claim 1 to a patient in need of such treatment.
8. A pharmaceutical composition, wherein the composition comprises:
a salt according to claim 2 , and
a pharmaceutically acceptable adjuvant, diluent, or carrier.
9. A method of treating chronic obstructive pulmonary disease, wherein the method comprises administering a salt according to claim 2 to a warm-blooded animal in need of such treatment.
10. A method according to claim 9 , wherein the warm-blooded animal is a human.
11. A salt according to claim 2 , which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ): 5.3, 10.5, 15.8, 16.5, 18.6 and 19.4.
12. A salt according to claim 2 , which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ): 5.3, 10.5, 15.8, 16.5, 18.6, 19.4, 19.7.
13. A salt according to claim 2 , which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ): 5.3, 10.5, 15.8, 16.5, 17.8, 18.6, 19.4, 19.7, 20.4 and 21.7.
14. A salt according to claim 2 , wherein the salt is an anhydrate.
15. A pharmaceutical composition, wherein the composition comprises:
a salt according to claim 14 , and
a pharmaceutically acceptable adjuvant, diluent, or carrier.
16. A method of treating chronic obstructive pulmonary disease, wherein the method comprises administering a salt according to claim 14 to a warm-blooded animal in need of such treatment.
17. A method according to claim 16 , wherein the warm-blooded animal is a human.
18. A pharmaceutical composition, wherein the composition comprises:
a salt according to claim 5 , and
a pharmaceutically acceptable adjuvant, diluent, or carrier.
19. A method of treating chronic obstructive pulmonary disease, wherein the method comprises administering a salt according to claim 5 to a warm-blooded animal in need of such treatment.
20. A method according to claim 19 , wherein the warm-blooded animal is a human.